Hal Barron, GSK R&D chief, at Endpoints News' UKBIO 2019
GSK’s latest pipeline review includes a slate of COPD programs headed to the scrap heap
GlaxoSmithKline R&D chief Hal Barron has tossed a lineup of COPD drugs out of the pipeline in the latest shift away from respiratory diseases. And …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
